BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21968353)

  • 1. Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections.
    Olson JA; Schwartz J; Hahka D; George A; Proffitt RT; Adler-Moore JP
    Antimicrob Agents Chemother; 2012 Jan; 56(1):218-30. PubMed ID: 21968353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
    Clemons KV; Espiritu M; Parmar R; Stevens DA
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4867-75. PubMed ID: 16304147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.
    Clemons KV; Schwartz JA; Stevens DA
    Med Mycol; 2011 Nov; 49(8):834-47. PubMed ID: 21539507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections.
    Olson JA; George A; Constable D; Smith P; Proffitt RT; Adler-Moore JP
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3884-94. PubMed ID: 20606065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
    Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF.
    Sionov E; Mendlovic S; Segal E
    J Antimicrob Chemother; 2005 Sep; 56(3):594-7. PubMed ID: 16006446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.
    Dennis CG; Greco WR; Brun Y; Youn R; Slocum HK; Bernacki RJ; Lewis R; Wiederhold N; Holland SM; Petraitiene R; Walsh TJ; Segal BH
    Antimicrob Agents Chemother; 2006 Feb; 50(2):422-7. PubMed ID: 16436692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection.
    Barchiesi F; Santinelli A; Biscotti T; Greganti G; Giannini D; Manso E
    J Antimicrob Chemother; 2016 Aug; 71(8):2230-3. PubMed ID: 27231274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
    van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice.
    Olson JA; Schwartz JA; Hahka D; Nguyen N; Bunch T; Jensen GM; Adler-Moore JP
    Med Mycol; 2015 Feb; 53(2):107-18. PubMed ID: 25550388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis.
    Kakeya H; Miyazaki Y; Senda H; Kobayashi T; Seki M; Izumikawa K; Yanagihara K; Yamamoto Y; Tashiro T; Kohno S
    Antimicrob Agents Chemother; 2008 May; 52(5):1868-70. PubMed ID: 18299412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.
    Lewis RE; Albert ND; Kontoyiannis DP
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4178-80. PubMed ID: 18725439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis.
    Sionov E; Mendlovic S; Segal E
    J Infect; 2006 Aug; 53(2):131-9. PubMed ID: 16360214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.
    Warn PA; Sharp A; Morrissey G; Denning DW
    Int J Antimicrob Agents; 2010 Feb; 35(2):146-51. PubMed ID: 20015618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis.
    Takazono T; Izumikawa K; Mihara T; Kosai K; Saijo T; Imamura Y; Miyazaki T; Seki M; Kakeya H; Yamamoto Y; Yanagihara K; Kohno S
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3508-10. PubMed ID: 19528281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
    Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
    J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
    Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
    Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
    Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
    J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful combined antifungal salvage therapy with liposomal amphothericin B and caspofungin for invasive Aspergillus flavus infection in a child following allogeneic bone marrow transplantation.
    Kriván G; Sinkó J; Nagy IZ; Goda V; Reményi P; Bátai A; Lueff S; Kapás B; Réti M; Tremmel A; Masszi T
    Acta Biomed; 2006; 77 Suppl 2():17-21. PubMed ID: 16918062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.